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Hyperactivation of CD4þ T cells is a hallmark of untreated HIV-1 infection. The
antigenic specificities of activated CD4þ T cells and the underlying mechanisms
leading to their activation remain thus far elusive. We report here that during HIV
rebound the dynamics of HIV-specific CD4þ T cells is highly correlated with the
dynamics of CD4þ T cells specific for persistent antigens derived from various
members of the herpes virus family, whereas CD4 responses towards non-
persistent antigens were unaffected by HIV replication. Notably, the dynamics
of HIV and herpes viral antigen-specific CD4þ T cells responses correlated with
the expression level of activation markers on dendritic cells (DCs) and activated
DCs were more potent in restimulating memory T cells. These data strongly
suggest that HIV replication costimulates activation of CD4þ T cells specific for
persistent herpes viral antigens via activation of DCs. We propose that a large
proportion of activated T cells during untreated HIV infection may be specific for
herpes viral antigens and identify a novel mechanism contributing to chronic
immune activation in untreated HIV-1 infection.
INTRODUCTION
Loss of CD4þ T cells alongside with aberrant immune activation
are hallmarks of HIV-1 pathogenesis. Hyperactivation of T cells
is in fact one of the best predictors of progression towards AIDS
(Giorgi et al, 1999; Sousa et al, 2002). The current paradigm is
based on the belief that the decline of CD4þ T cells relies largely
on activation-induced cell death rather than productive
infection and subsequent killing of activated CD4þ T cells
(Bangs et al, 2006; Douek et al, 2003; Grossman et al, 2006;
Silvestri & Feinberg, 2003). The majority of activated CD4þ T
cells is neither HIV-infected nor HIV-specific (Douek et al, 2002;
Kaiser et al, 2007). The mechanisms underlying this bystander
activation of non-HIV-specific CD4þ T cells are still poorly
defined (Bangs et al, 2006). Systemically translocating lipopo-
lysaccharide (LPS) due to increased permeability of the gut
epithelium is suggested to contribute to the general immune
activation (Brenchley et al, 2007). However, the exact
mechanisms how this translates into activation of CD4þ T cells
remain undefined.
So far no insights about the specificity—and perhaps a
specificity bias—of the activated CD4þ T cells are known.
Bystander activation of CD4þ T cells during HIV-1 infection
has largely been described being independent of antigen
specificity and is often loosely attributed to the presence of
pro-inflammatory cytokines during untreated HIV-1 infection
(Bangs et al, 2006, 2009). However, a dependence on antigen
specificity for CD4þ T cell activation during HIV infection—for
example, through gut-derived antigens (Brenchley et al, 2007),
self-antigens (Rawson et al, 2007) or (reactivation of) persistent
viruses (Bangs et al, 2006)—could so far not be excluded as the
antigen specificities of hyperactivated CD4þ T cells in chronic
HIV-1 infection are unknown.
Here we show in a large longitudinal study set-up that HIV
replication, upon cessation of antiretroviral therapy (ART),
specifically leads to activation of CD4þ T cells with specificities
for low level persistent herpes virus antigens in the absence of
detectable reactivation of these members of the herpes virus
family. Thus, we propose that HIV-1 directly or indirectly
provides costimulation for CD4þ T cells which is dependent on
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antigen specificity and requires the presence of low levels of
persistent antigens. We provide evidence that ongoing HIV
replication induces activation of dendritic cells (DCs) in vivo
which correlates with the activation of CD4þ T cell responses
specific for persistent antigens of the herpes virus family. These
findings strongly suggest that DCs foster the activation of
persistent viral antigen-specific CD4þ T cells through an
improved efficiency in antigen presentation upon their activa-
tion during HIV rebound.
RESULTS
HIV-1 rebound drives expansion of CD4R T cells with
specificities for herpes viral antigens
CD4þ T cell depletion and chronic immune activation are major
characteristics of HIV-1 infection; however, their causal relation
is poorly defined. To investigate the impact of HIV replication on
immune activation, with particular interest towards the
specificities of CD4þ T cells which become activated during
HIV recrudescence, we analysed the in vivo dynamics of HIV-
specific and non-HIV-specific CD4þ T cells in a cohort of 14
patients undergoing interruption of ART. We observed that
increases in plasma viral load boosted HIV-specific CD4þ T cell
responses in the majority of patients. Remarkably though,
cytomegalovirus (CMV) specific CD4þ T cells followed
comparable dynamics despite the absence of CMV viraemia.
In striking contrast, CD4þ T cells specific for tetanus toxoid (TT)
or streptokinase-streptodornase (SKSD) were not influenced by
HIV replication, suggesting that HIV may explicitly expand
CD4þ T cells specific for persistent antigens (Supporting Fig 1
and Table 1). To corroborate and extend these findings in a
larger patient cohort withmore T cell specificities, we performed
a detailed longitudinal analysis of 32 patients interrupting ART
and thus experiencing viral rebound (patient details are
summarized in Table 1). We measured the frequencies of
HIV-specific CD4þ T cells, of CD4þ T cell specific for a variety of
persistent antigens of the herpes virus family (CMV, Epstein–
Barr virus (EBV), herpes simplex virus (HSV) 1/2, varicella-
zoster virus (VZV)) and of CD4þ T cells specific for the non-
persisting, bacterial antigens TT or SKSD. Due to limited
availability of cells and/or the absence of detectable responses,
other non-persistent antigens such as Influenza A and measles
could not be included in this study.
For each patient multiple samples before and after treatment
interruption were analysed. In line with our previous results and
other reports, HIV-1 recrudescence induced a dynamic response
of the HIV-specific CD4þ T cell population. However, confirming
our previous finding, ensuing HIV replication also affected the
dynamics of CD4þ T cell responses towards non-HIV antigens,
namely CD4þ T cell responses specific for the herpes family
viruses CMV, EBV, HSV1/2, and VZV, all of which form latent,
persistent infections. Importantly, the dynamics of the HIV-
specific and the CMV-, EBV-, HSV1/2- and VZV-specific CD4þ T
cells were highly correlated (Fig 1A and B). In contrast, no
correlation was found between HIV-specific CD4þ T cell
responses and CD4þ T cell responses specific for the two non-
persistent bacterial antigens SKSD and TT. The significance of
this correlationwas verified by two different correlation analyses;
Spearman’s correlation (RS) (Fig 1B and C) and dynamical
correlation analysis (Table 2) (Dubin & Mueller, 2005). The more
strict dynamical correlation analysis (RD) accounts for the fact
that multiple data points originate from the same individual and
are thus inter-correlated (Dubin & Mueller, 2005). Furthermore,
the observed correlation between the dynamics of HIV-specific
CD4þ T cell responses and CD4þ T cell responses specific for
persistent antigens is dependent onHIV rebound as no correlation
was found in a matching control cohort which remained
continuously on ART (Fig 1C). Interestingly, in the absence of
HIV-1 replication SKSD- and TT-specific CD4þ T cell responses
tend to correlate with the HIV-specific CD4þ T cell response.
During successful, highly active ART HIV replication may be
suppressed to a level that its state may be described as non-
persistent and it is conceivable that the dynamics of non-
persistent antigen-specific CD4þ T cells correlate.
Thus, an increase in plasma virus load (pVL) boosted HIV-
specific CD4þ T cell responses, indicating that HIV reactivation,
and hence an increase of antigen load promotes HIV-specific
CD4þ T cell expansion. The similar dynamics of the HIV-, CMV-,
EBV-, HSV1/2- and VZV-specific CD4þ T cell responses
demonstrates that rebounding HIV replication does not exclu-
sively affect the frequencies of HIV-specific CD4þ T cells but also
of CD4þ T cells with specificities for other persistent antigens.
It is conceivable that upon HIV rebound, persistent latent
infections such as CMV, EBV, HSV and VZV might also
reactivate in vivo and hence induce stimulation of the respective
CD4þ T cells. To investigate this, plasma samples from all
patients were analysed for CMV and EBV viraemia by
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Table 1. Characteristics of patient cohort B
HIV positive Days Max HIV (copies 103/ml)
Study
group
Age
(years)
Gender Before ART On-ART Included in study Before ART Off-ART CD4 counts (cells/ml)
n Median
(range)
Male (%) Month Median (range) Median (range) Median (range) Median (range) Median (range)
Stop-ART Before ART-Stop Before ART-Slop
32 39 (27–59) 84 <6 537 (152–1491) 409 (238–1179) 173 (4–31,300) 22 (0.25–770) 706 (347–1419)
Control Before study First time-point studied
12 37 (31–60) 83 <6 267 (24–2395) 858 (270–1319) 191 (17–655) – 589 (265–1223)
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quantitative polymerase chain reaction (PCR) at baseline (‘on-
ART’) and at a time-point at which CMV-specific CD4þ T cell
frequencies started to increase (‘off-ART’). We chose to quantify
CMV and EBV DNA in the plasma as this shouldmore accurately
reflect virus reactivation compared to DNA analysis within
whole peripheral blood mononuclear cells (PBMCs), where
CMV and EBV DNA content will largely reflect latent viral
genomes (Compston et al, 2008; Kaur et al, 2003; Torre-Cisneros
et al, 2005). CMV or EBV DNA copies were only detected in 3 of
44 analysed plasma samples after cessation of ART, all other
samples were below detection limit, indicating that no
systemically measurable CMV and EBV reactivation occurred
(Supporting Table 2). In addition, significant CMV reactivation
was unlikely to occur in our patient cohort as they were not
immunosuppressed owing to early initiation of therapy during
the acute phase of infection and owing to the early stage of HIV
disease progression. Moreover, CD4 counts were in all cases
above 350 cells/ml when ART was stopped. In support of this
notion, a study conducted in the Rhesus macaque model
showed that CMV reactivation is only detected in the late stages
of disease during pronounced immunosuppression which was
associated with high loss of CMV-specific immunity (Kaur et al,
2003). While it formally cannot be excluded that potentially low
levels of CMV and EBV replication may occur locally and thus
contribute to the stimulation of the respective CD4þ T cell
responses, our correlated kinetic data suggest a direct link
between HIV viraemia and CD4þ T cell responses specific for
HIV and the investigated persistent herpes viruses.
Taken together, our results strongly suggest that HIV rebound
exerts a ‘costimulatory’ function for the activation of CD4þ T
cells with specificities for persistent viral antigens. ‘Costimula-
tion’ implies that the activation of the CD4þ T cells is also
dependent on the presence of (low levels of) cognate antigen. It
is known for CMV, EBV and HSV that low levels of viral DNA are
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Figure 1. Study cohort B: Dynamics of HIV-specific CD4R T cells and CD4R T cells specific for persistent viral antigens correlated after HIV rebound.
A. Dynamics of HIV (triangles)- and CMV (circles)-specific CD4þ T cell responses in two representative patients with (#2) or without (#C12) ART-Stop. The shaded
area depicts pVL.
B. Correlation analysis of HIV-specific CD4þ T cell responses and other antigen-specific CD4þ T cell responses in the ART-stop cohort.
C. Correlation analysis of HIV-specific CD4þ T cell responses and other antigen-specific CD4þ T cell responses in the control cohort.
Each individual point represents one measurement. N indicates the number of measurements. Spearman’s nonparametric correlation was performed with a
two-tailed significance; p indicates the p-value and RS the Spearman’s correlation coefficient. Frequencies of antigen-specific CD4
þ T cells are indicated as spot
forming cells (SFC) per 1106 purified CD4þ T cells.
www.embomolmed.org EMBO Mol Med 2, 231–244  2010 EMBO Molecular Medicine 233
constantly detectable in the saliva (Griffin et al, 2008),
supporting the notion that virus antigens, albeit at minute
concentrations, are constantly produced. In the absence of HIV
replication, these low levels of locally produced antigens might
not suffice to induce full activation of specific CD4þ T cells.
However, in the presence of HIV replication, the stimulation
threshold of these persistent antigen-specific CD4þ T cells might
be lowered through overall changes of the milieu allowing for
their full activation and expansion.
HIV-driven activation of CMV-specific CD4R T cells can be
directly linked to markers of chronic immune activation
As we had observed that HIV recrudescence leads to the
expansion of CD4þ T cells which are specific for persistent
antigens, we hypothesized that HIV rebound also induced the
up-regulation of activation markers which are indicative for
‘chronic immune activation’ in HIV-1-infected individuals. In
five representative patients CD38 and HLA-DR expression was
analysed on- and off-ART on total CD4þ and CMV-specific CD4þ
T cells (Fig 2A and B).
Indeed, the percentage of CD38þ HLA-DRþ cells among total
CD4þ T cells was significantly (p< 0.05, paired t-test; data pairs
analysed N¼ 5) increased off-ART. Simultaneously, these
activation markers were up-regulated significantly (p< 0.05,
paired t-test; data pairs analysed N¼ 5) to even higher degrees
on CMV-specific CD4þ T cells (Fig 2B). Thus, HIV-1 rebound
mediated costimulation is therefore reflected both by the
expansion of CMV-specific CD4þ T cells as well as by up-
regulation of the classical activation markers HLA-DR and CD38
which characterize chronic immune activation in HIV-1
infection. Although our longitudinal quantification of antigen-
specific T cell responses was limited to CD4þ T cells, we also
analysed whether viral rebound led to increased immune
activation within total and CMV-specific CD8þ T cell popula-
tions, in particular since the immune activation status of CD8þ T
cells is the best predictor of disease progression (Giorgi et al,
1999). Up-regulation of activation markers on total CD8þ and
CMV-specific CD8þ T cells occurred in all tested patients to
similar degrees as was observed for CD4þ T cells (Fig 2A and B).
In addition, preliminary observations in a small number of
patients from study cohort A suggest that also HIV- and CMV-
specific CD8þ T cell responses exhibit similar dynamics upon
treatment interruption (Supporting Fig 2). These observations
lend support to the hypothesis that HIV-1 rebound might not
only costimulate activation of CD4þ T cells with specificities for
persistent herpes viruses, but also the respective CD8þ T cells.
We are currently enrolling patients for a new study to address
this important question.
HIV rebound is not associated with elevated levels of plasma
LPS, sCD14 or pro-inflammatory cytokines
We next investigated several potential mechanisms by which
HIV-1 rebound might costimulate the activation of CD4þ T cells
specific for persistent herpes viral antigens. We hypothesized
that potentially increased levels of LPS or pro-inflammatory
cytokines off-ART might drive the costimulation of CD4þ T cell
responses. LPS and pro-inflammatory cytokines could mediate
direct costimulatory effects on CD4þ T cells or act indirectly via
activation of antigen-presenting cells. To test this hypothesis,
we longitudinally measured plasma LPS levels and pro-
inflammatory cytokine levels on- and off-ART. Five patients
with relative high levels of HIV rebound (>1.5 105 RNA
Research Article
Bystander T cell activation in HIV-1 infection
Table 2. Dynamical correlation analysis
Stop-ART Controls
HIV-specific response1 CD40, pDCs2 CD40, mDCs3 HIV-specific
response
RD HIV-specific response 0.37
 0.07
p-value 4.7T 105 0.24
RD CMV-specific response 0.33
 0.37 0.51 0.02
p-value 9T108 7.4T 105 7T 108 0.57
RD EBV-specific response 0.27
 0.11 0.38 0.06
p-value 8T106 0.13 7.2T105 0.31
RD HSV1þ 2-specific response 0.05 0.25 0.31 0.13
p-value 0.25 0.006 0.001 0.13
RD VZV-specific response 0.15
 0.15 0.29 0.17
p-value 0.02 0.91 0.99 0.93
RD SKSD-specific response 0.07 0.08 0.14 0.25
p-value 0.86 0.77 0.91 0.02
RD TT-specific response 0.01 0.37 0.37 0.27
p-value 0.55 1.00 1.00 0.009
1‘‘specific response’’ indicates ‘‘specific CD4þT cell response’’.
2CD40 expression level on mDCs.
3CD40 expression level on pDCs.
RD, dynamic correlation coefficient.
p<0.05.
p<0.01.
Bold indicates statistically significant correlations.
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copies/ml) were chosen as it seemedmost likely that altered LPS
or cytokine levels would be detectable in these individuals. LPS
translocation from the gut is suggested to contribute to chronic
immune activation in HIV-1 infection and was shown to be
elevated in the chronic phase of the disease (Brenchley et al,
2007). In our study, plasma LPS levels were not affected by HIV-
1 rebound (Fig 3). The absence of increased levels of LPS
(>100 pg/ml) was verified by four different tests designed to
detect endotoxin. It should be noted that our patient cohort
initiated ART during the acute phase of HIV infection and might
thus exhibit reduced gastrointestinal damage and LPS translo-
cation. Further, with our measurements in the plasma we
cannot exclude locally elevated levels of LPS, e.g. in the gut-
associated lymphoid tissue. In addition, we also measured
soluble CD14 (sCD14) as a surrogate biomarker for increased
levels of LPS (Brenchley et al, 2007). In line with our LPS
measurements, sCD14 levels were not affected by HIV-1
rebound (Fig 3) and did not correlate with the magnitude of
the HIV-specific CD4þ T cell response or the levels of LPS in the
few samples where we could detect LPS (Supporting Fig 3).
Comparable to the LPS analyses, pro-inflammatory cytokines
(IL-2, -6, -10, IFNg, TNFa, IFNa) remained below detection limit
in the studied plasma samples, even during HIV rebound (Fig 3).
Again, this does not exclude locally elevated levels at sites of
inflammation and/or virus replication. The failure to detect
elevated cytokine levels in the plasma is not unexpected as it
was recently published that even during primary infection
elevated levels of plasma cytokines were not detectable in all
patients and increased rather transiently, e.g. for IFNa also with
very rapid kinetics (Stacey et al, 2009). The timing of our
samples might thus have missed transient increases. Of note,
pro-inflammatory cytokines could be detected during the acute
phase of primary HIV-1 infection in samples from the same
patients (data not shown).
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Figure 2. CMV-specific CD4R and CD8R T cells
up-regulate activation markers upon HIV
rebound. CD38 versus HLA-DR expression was
analysed on total and CMV-specific CD4þ and CD8þ
T cells in the same patients on- and off-ART.
A. Shows stainings of one representative patient
(#30). Numbers indicate % of CD38þ HLA-DRþ
cells gated on total or CMV-specific CD4þ and
CD8þ T cells.
B. Percentage of CD38þ HLA-DRþ cells among total
or CMV-specific CD4þ and CD8þ T cells in five
patients on- compared to off-ART. CMV-specific
T cells were identified as IFN-gþ cells upon
restimulation with CMV peptides.
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HIV-1 rebound drives activation of dendritic cells
Since we detected a preferential activation of CD4þ T cells
specific for persistent but not of those specific for non-persistent
antigens, we reasoned that HIV rebound might be associated
with the activation and maturation of DCs which renders these
cells more efficient in antigen presentation and might thus allow
CD4þ T cell stimulation despite the low levels of the persistent
antigens. Our analyses did not support a dominant effect of LPS
and pro-inflammatory cytokines, however, several in vitro
(Fonteneau et al, 2004; Harman et al, 2006; Smed-Sorensen et al,
2005) and ex vivo (Barron et al, 2003; Dillon et al, 2008; Mandl
et al, 2008; Tilton et al, 2008) studies indicate that HIV itself
directly affects the maturation status of DCs. In particular CD40
was suggested to be expressed at increased levels on blood DCs
from HIV-infected individuals, as assessed in cross-sectional
studies (Barron et al, 2003; Dillon et al, 2008). We decided to
measure directly the impact of HIV recrudescence on ex vivo
CD40 and CD86 expression levels on plasmacytoid (pDCs) and
myeloid (mDCs) blood dendritic cells within individual patients.
To this end we longitudinally assessed these activation markers
on pDCs and mDCs in a subset of 15 rebound patients and 5
control patients (Figs 4 and 5). Longitudinal samples were
analysed from the same time-points as were studied for CD4þ T
cell responses, LPS and cytokine levels. While changes in CD86
expression were too small to draw firm conclusions (data not
shown), CD40 expression was significantly up-regulated on
mDCs as well as pDCs upon HIV rebound (Figs 4B and 5). Most
importantly, the levels of CD40 expression were positively
correlated with the magnitude of CD4þ T cell responses specific
for HIV, CMV, EBV and HSV (Fig 5A and Table 2). No such
correlation was found between CD40 expression levels on DCs
and the size of the CD4þ T cell response against the two non-
persistent antigens (Fig 5B). In the control cohort (patients
under continuous ART) the expression levels of CD40 on mDCs
and pDCs were about 1 log lower than after HIV rebound in the
ART-Stop cohort and were not significantly modulated over the
time course of analysis. Furthermore, in these patients, the CD40
expression levels did not correlate with HIV-specific CD4þ T cell
frequencies (Fig 5C).
Although we failed to detect elevated levels of LPS upon
treatment interruption and viral rebound (which would be a
potent activator of DCs), nor did we detect marked variations of
sCD14 levels (as surrogate marker for increased LPS levels), we
nonetheless tested whether sCD14 levels correlated with the
activation status of DCs. We could not detect a significant
positive correlation between sCD14 and CD40 expression levels
on pDCs or mDCs (Supporting Fig 3).
Activated DCs are more potent in reactivating CMV-specific
CD4R T cell responses
Our hypothesis that CD4þ T cells specific for herpes viral
persistent antigens are more effectively restimulated by
activated DCs, especially in the setting of limiting amounts of
antigen, requires experimental validation. We therefore gener-
ated immature monocyte-derived DCs in vitro, activated those
either with LPS or with AT-2-inactivated HIV particles (iHIV)
and pulsed them with limiting concentrations of overlapping
CMV-derived peptides. These DCs were then used to restimulate
autologous purified bulk CD4þ T cells from CMV-positive
donors. Activated DCs (either by LPS or by iHIV) consistently
induced markedly enhanced proliferation of CMV-specific CD4þ
T cells compared to non-activated DCs (Fig 6A–C) (p< 0.05,
paired t-test; Number of individuals tested N¼ 3), indicating
that also antigen-experienced CD4þ T cells profit from the
activation status of DCs, in particular under limiting antigen
concentrations. So far it has only been shown that iHIV-
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Figure 3. Plasma LPS levels, sCD14 and pro-inflammatory cytokines are not elevated during HIV rebound. Plasma LPS levels (open diamonds), sCD14 (closed
triangles) and plasma cytokine concentrations (closed circles) weremeasured longitudinally before and during HIV rebound in five representative patients. Shaded
areas depict pVL. The detection limits for the plasma cytokines were: IL-2, 8 pg/ml; IL-6, 10 pg/ml; IL-10, 10 pg/ml; IFNg, 40 pg/ml; TNFa, 10 pg/ml; IFNa, 25 pg/ml.
236  2010 EMBO Molecular Medicine EMBO Mol Med 2, 231–244 www.embomolmed.org
activated DCs enhance allogenic T cell responses—which are
mostly naı¨ve T cells (Harman et al, 2006).
DISCUSSION
Themechanisms underlying hyperactivation of non-HIV-specific
CD4þ T cells during chronic HIV-1 infection are still poorly
understood. Here, we show that HIV replication preferentially
costimulates activation of CD4þ T cells with specificities for
persistent herpes virus family members. We provide strong
circumstantial evidence that this activation (in the absence of
reactivation of the herpes viruses) is mediated through HIV
replication induced activation of DCs, which could in turn
provide more efficient presentation of low level persistent
antigens to the CD4þ T cells. As this mechanism requires the
presence of cognate antigen, it excludes CD4þ T cells with
specificities for non-persistent antigens. Indeed, in our in vivo
studywe have not observed that HIV reboundwould affect CD4þ
T cell responses specific for non-persistent antigens similarly to
those with specificities for persistent antigens.
There is other evidence in the literature suggesting specific
effects of HIV infection on CMV and other persistent antigen
specific CD4þ T cells. For instance, in a cross-sectional
study, higher frequencies of CMV versus mumps-specific CD4þ
T cells were reported in HIV positive compared to uninfected
individuals (Waldrop et al, 1997). Elevated frequencies of blood
CMV-specific IFNg-secreting CD4þ T cells were also reported in
another study comparing HIV progressors to LTNP or HIV-
uninfected individuals (Harari et al, 2004a). In addition, elevated
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Figure 4. CD40 expression on peripheral blood dendritic cells increases during viral rebound and follows similar dynamics as HIV- and CMV-specific CD4R T
cell responses.
A. Flow cytometric gating strategy for peripheral blood myeloid DCs (mDCs) (lin, HLA-DRþ, CD123þ, CD11cþ), and plasmacytoid DC (pDCs) (lin, HLA-DRþ,
CD123þ, CD11c).
B. CD40 expression levels on pDCs (open diamonds, red line) and on mDCs (open circles, blue line) are plotted together with CMV (closed circles)- and HIV (closed
triangles)-specific CD4þ T cell responses in two representative patients with (#22) or without (#C9) ART Stop. Shaded areas indicate pVL.
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frequencies of CMV-specific CD4þ T cells were found to correlate
with stronger HIV-specific CD4þ T cell responses (Pitcher et al,
1999). Furthermore, in the case of CD8þ T cell responses, CMV-
and EBV-specific CD8þ T cells were described to exhibit a more
activated phenotype during primary HIV infection compared to
flu-specific CD8þ T cells (Doisne et al, 2004).
Such a mechanism of HIV mediated costimulation of CD4þ T
cells with specificities for persistent viruses requires the
presence of low levels of cognate antigen, but would be
independent of overt reactivation of heterologous viruses. In
case of persistent, latent herpes virus infections, low levels of
persistent viral antigens are very likely to be continuously
present in the host. Although it is impossible to quantify the
amount of this low level antigen expression (even in the mouse,
Reddehase et al, 2008), several indirect measures strongly
support the presence of low level antigen expression; compared
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Figure 5. CD40 expression on peripheral blood dendritic cells correlates with the dynamics of the HIV-, CMV-, EBV- and HSV1R2-specific CD4R T cell
responses during viral rebound.
A. Correlation analysis between CD40 expression levels and the frequencies of HIV- and Herpes virus-specific CD4þ T cell responses and HIV plasma viral load.
B. Correlation analysis between CD40 expression levels and the frequencies of non-persistent antigen-specific CD4þ T cell responses and HIV plasma viral load.
C. Low expression levels of CD40 on mDC and pDC in the control cohort.
Each individual point represents one measurement. N indicates the number of measurements. Spearman’s non-parametric correlation was performed with a
two-tailed test of significance; p indicates the p-value and RS the Spearman’s correlation coefficient.
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to TT-specific CD4þ T cells (non-persistent antigen), most CMV-,
EBV-, HSV- and VZV-specific CD4þ T cells exhibit a more
effector–memory phenotype which is likely to be indicative for
repetitive antigen encounter and persistent, low antigen load
(Harari et al, 2004b; Jones et al, 2007). Furthermore, in the
murine and human CMV infection, a slow accumulation of CMV-
specific T cells with effector–memory phenotypes is observed
and has been ascribed to constant low level exposure to cognate
antigen (Karrer et al, 2003; Komatsu et al, 2003; Snyder et al,
2008). In humans, DNA of CMV, EBV and HSV is regularly shed
into the saliva suggesting that low antigen load should be
present systemically (Griffin et al, 2008). In case of HIV-infected
individuals, the quantity of shedding was reported to be
independent of therapy status (to our knowledge ART has no
direct antiviral effects on viruses of the herpes family), CD4
counts or pVL (except for EBV and pVL) (Griffin et al, 2008),
which is in line with our data showing that CMV or EBV are not
systemically reactivated in our patient cohort upon ART
interruption. Although we cannot completely exclude simulta-
neous reactivation of persistent viruses, perhaps restricted to
specific anatomical sites, as a major driver for the activation of
the respective CD4þ T cells, this seems rather unlikely as we
observed a highly synchronous, concerted activation of herpes
virus family-specific and HIV-specific CD4þ T cells following
ART interruption. This rather points to a common source for
activation. In addition, the viruses studied here persist in
different cell types and are likely to depend on different stimuli
for their reactivation from latency, which makes a simultaneous
reactivation upon ART interruption to appear even less
plausible. Apart from the ‘common’ members of the herpes
virus family as studied here, KSHV (the causative oncovirus of
Kaposi’s Sarcoma) has increased prevalence in HIV-infected
individuals and is associated with a negative disease outcome.
It also establishes persistent infection, which is in immuno-
competent individuals usually well suppressed and free of
symptoms. KSHV is very likely relevant for our study aswell as it
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Figure 6. Activated DCs are more potent in restimulating CMV-specific CD4R T cells.
A. Representative histograms showing proliferation of CD4þ T cells as measured by CFSE dilution. Purified bulk CD4þ T cells from CMV seropositive donors were
stimulated with autologous monocyte-derived DCs (MDDCs) which had been activated by LPS, AT-2-inactivated HIV particles (iHIV) or were left unactivated.
MDDCs were pulsed with or w/o limiting amounts of overlapping CMV-derived peptides. The dashed line indicates culture with unpulsed MDDCs, the solid line
indicates culture with CMV peptide-loaded MDDCs. The indicated percentage of CFSE low cells refers to stimulation with CMV peptide-pulsed MDDCs.
B. Proliferative responses of CD4þ T cells stimulated with CMV-loaded MDDCs in 3 healthy CMV-positive donors. MDDCs were activated with LPS.
C. Proliferative responses of CD4þ T cells stimulated with CMV-loaded MDDCs in 3 healthy CMV-positive donors. MDDCs were activated with
iHIV particles.
Error bars indicate standard deviation between 3 samples in the same experiment.
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could serve as an additional source of persistent low levels of
antigen (Edelman, 2005).
Our data suggest that more efficient presentation of very low
levels of persistent antigens by activated DCs is responsible for the
activation of persistent-antigen specific CD4þ T cells during HIV
replication. This defines a new role for DCs in HIV pathogenesis.
As shown here and previously by others in vitro (Fonteneau et al,
2004; Harman et al, 2006; Smed-Sorensen et al, 2005; Tilton et al,
2008) and in vivo (Barron et al, 2003; Dillon et al, 2008), HIV has
direct activatory effects on DCs, likely through viral-derived TLR
7/8 ligands such as ssRNA. Our data highlight further that TLR-
ligand activated DCs or DCs activated by iHIV particles are
superior in their ability to restimulate antigen-experienced T cells
compared to their non-activated counterparts—in particular at
limiting antigen concentrations. In line with our results it has been
reported that TLR-ligand activated DCs induce enhanced CMV-
specific CD4þ T cell responses (Lore et al, 2003).
Our data complement a recent study—which, however, has
not been confirmed by others (Lederer et al, 2009)—showing
that activation of DCs upon simian immunodeficiency virus
(SIV) infection is at least partially impaired in a non-pathogenic
model of SIV infection, in contrast to a pathogenic model of SIV
infection or the HIV-driven activation of human DCs (Mandl et
al, 2008). The differential activation of DCs from natural hosts
compared to non-natural hosts upon SIV/HIV exposure was
ascribed to inherent differences in TLR-mediated signalling and
resulted in strong type 1 interferon production in DCs from non-
natural monkey hosts or from humans (Mandl et al, 2008). Type
1 interferons have been shown to provide a potent ‘signal 3’ for
the activation of T cells (Haring et al, 2006; Havenar-Daughton
et al, 2006; Pape et al, 1997).
A current paradigm postulates that systemic microbial
translocation from the gut leads to increased systemic LPS
levels in HIV-infected individuals due to increased permeability
of the gut epithelium (Brenchley et al, 2007). A recent study,
however, failed to detect changes in levels of LPS and sCD14
during disease progression (Redd et al, 2009).
How elevated LPS levels would specifically translate into an
increased activation status of T cells remains to be defined. We
therefore analysed in our patient cohort whether increased
systemic LPS levels were evident after ART interruption and
whether they would correlate with the observed DC activation and
the dynamics of T cell responses.We could not detect elevated LPS
levels in the plasma, rendering it unlikely that LPS is the major
driving force for the in vivo activation of DCs. However, it cannot
be excluded that elevated LPS levels are present at specific
anatomical sites such as in intestinal tissue and impact locally on
the activation of DCs. In line with the absence of systemic
detectable LPS upon ART interruption, we were not able to detect
inflammatory cytokines in plasma upon HIV rebound. The
absence of systemically elevated cytokine levels is not surprising
as it was recently published that even during primary infection
elevated levels of plasma cytokines were not detectable in all
patients andwere present only very transiently (Stacey et al, 2009).
Innate stimuli especially TLR ligands as well as pro-
inflammatory cytokines can directly lead to the activation of
DCs but are also thought to be able to directly impact on T cell
activation—a mechanism which is so far not well defined. A
direct role for TLR ligands in the activation of T cells has been
shown for costimulation of CD4þ T cells, e.g. by TLR7/8 ligands
in the presence of low levels of simultaneous T-cell antigen
receptor (TCR) stimulation (Caron et al, 2005; Kabelitz, 2007).
Such a costimulatory effect of TLR ligands on activation of T cells
in the presence of limiting antigen levelswouldwell fitwith our in
vivo data and cannot be excluded, perhaps in addition to the TLR-
mediated activation of DCs. Additionally, a recent in vitro model
of bystander activation showed that soluble factors secreted upon
TCR stimulation by CD4þ T cells can induce a partially activated
phenotype in bystander CD4þ T cells, but fail to induce their
proliferation (in the absence of TCR stimulation) (Bangs et al,
2009). Furthermore, as mentioned earlier, inflammatory cyto-
kines such as type 1 interferons or IL-12 have been shown to
provide a potent ‘signal 3’ for the activation of murine T cells in
close proximity with signals 1 and 2 (Haring et al, 2006;
Havenar-Daughton et al, 2006; Way et al, 2007).
In conclusion, innate stimuli and cytokines which are
associated with HIV replication may provide costimulatory
signals to CD4þ T cells either directly or as we show here, more
likely indirectly through activation of DCs (Fig 7). As discussed
above, this costimulation by HIV requires the presence of at least
minimal levels of cognate antigen to induce full activation of
CD4þ T cells, since only persistent-antigen specific CD4þ T cells
were activated in our study.
As a consequence a large proportion of hyperactivated CD4þ
T cells which appear upon HIV infection may be specific for
persistent, non-HIV antigens. Activation of DCs by HIV likely
plays a critical role in this process and defines a new antigen-
dependent mechanism of bystander activation of CD4þ T cells,
unravelling a further constituent of the chronic immune
activation and CD4þ T cell loss in HIV infection.
In addition, our findings indicate a new role for persistent
herpes virus infections in HIV-1 pathogenesis. Herpes virus
infections arewell described to facilitate HIV-1 acquisition (HSV-
2) and are major drivers of AIDS mortality (CMV reactivation).
We describe here that they might also contribute significantly to
chronic immune activation. This underpins the beneficial role of
early initiation of ART as a means to limit immune activation in
order to preserve T cell immunity during HIV-1 infection.
MATERIALS AND METHODS
Study population
We recruited two study cohorts (A and B). In study cohort A, eight
HIV-positive individuals who initiated ART during the chronic phase of
infection and six patients who initiated ART during acute infection were
included (Supporting Table 1) (Trkola et al, 2005). In the study cohort B,
44 HIV-positive individuals were recruited who initiated ART during the
acute phase of infection (Table 1 and Supporting Table 3). These patients
participated in the Zurich primary HIV-1 infection study (ZPHI), a
prospective long-term observational single centre study. In this protocol
patients are offered early ART during the acute phase of infection and
after 1 year of suppressed viraemia (<40 HIV-1 RNA copies/ml plasma)
patients can choose to interrupt ART. The following criteria were used to
Research Article
Bystander T cell activation in HIV-1 infection
240  2010 EMBO Molecular Medicine EMBO Mol Med 2, 231–244 www.embomolmed.org
define acute infection: (a) acute retroviral syndrome (ARS) and negative
or indeterminate Western blot in the presence of a positive p24 Ag and/
or detectable plasma HIV-1 RNA or (b) documented seroconversion with
or without symptoms within 90 days. Study details are listed under
www.clinicaltrials.gov; ID NCT00537966. All individuals of study cohort
B were screened positive for CMV, EBV, HSV1þ2 and VZV by serology
prior to enrolment. In study cohort B, 32 patients interrupted ART
(rebound cohort) and 12 patients remained continuously on ART
(control cohort). Approval of the ethical committee and written
informed consent from all subjects were obtained according to the
guidelines of the University Hospital Zurich.
Quantification of CMV and EBV DNA
CMV and EBV DNA were quantified in plasma samples as previously
described (Yun et al, 2000; Zingg et al, 1999). The detection limit was
200 copies/ml as values below 200 copies cannot be reproduced with
statistical confidence.
Generation of MDDCs
Monocyte-derived dendritic cells (MDDCs) were generated from
freshly isolated PBMCs according to standard procedures as described
elsewhere (Harman et al, 2006).
IFN-g ELISpot assay
CD4þ T cells were isolated by magnetic microbeads (Miltenyi) from
cryopreserved PBMCs and co-cultured with 10% fresh autologous
MDDCs. Cells were stimulated in an IFN-g ELISpot as described
elsewhere (Oxenius et al, 2000). Briefly, cells were stimulated over-
night with an HIV gag pool (NIH AIDS Reagent), CMV, HSV1þ2, VZV
lysates (Virion), EBV lysate (Virusys), an SKSD preparation (Cyanamid
Iberica, SA) or TT (gift from Novartis Vaccines). The number of spot
forming cells (SFC) was calculated by subtracting an unstimulated
control as background. Spots were quantified using an automated
spot counter (AID). If not stated differently, antigen-specific CD4þ T cell
responses are shown as SFC/1106 CD4þ T cells.
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Figure 7. Proposed mechanisms of how HIV replication induces activation of CD4R T cells with specificities for persistent viral antigens. In the absence of
HIV replication—and thus in the absence of inflammation and/or HIV-derived pathogen-associated molecular patterns (PAMPs)—dendritic cells do not show an
activated phenotype and are not very efficient in restimulating CD4þ T cells specific for low levels of latent persistent viral antigens (left side). However, in the
presence of ongoing HIV replication, DCs exhibit an activated phenotype and are more effective in restimulating CD4þ T cells specific for latent persistent viral
antigens in particular in the setting of limiting antigen levels, as is likely the case in vivo for these latent viral infections (right side). Activation of DCs might be
triggered by PAMPs (either HIV derived such as ssRNA or perhaps derived from bacteria which translocate systemically from the gut lumen) or by pro-
inflammatory cytokines such has TNFa or type I interferons which are locally produced in tissues with active HIV replication. In addition pro-inflammatory
cytokines may exert direct costimulatory effects on CD4þ T cells.
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Flow cytometry
For CD4þ T cell immunophenotyping cryopreserved PBMCs were
thawed and rested over-night before stimulation for 6 h with or
without CMV pp65 and IE-1 overlapping peptide pools in the
presence of Monensin- and Brefeldin-A (Sigma). Cells were surface
stained with anti-CD4 Am-Cyan, anti-CD3 Pacific-blue, anti-CD38
APC, anti-HLA-DR APC-H7 (all BD) followed by intracellular staining
with anti-IFN-g PE-Cy7 (BD) and anti-IL-2 FITC (Biolegend). CMV-
specific CD4þ T cells were identified as IFN-gþ in the stimulated
sample.
For DC analysis cryopreserved PBMCs were thawed and immedi-
ately surface stained with anti-lineage-1 (lin-1: CD3, CD14, CD16,
CD19, CD20, CD56) FITC, anti-CD34 FITC, anti-HLA-DR APC-H7, anti-
CD123 PerCp-Cy5.5 (all BD), anti-CD11c Biotin (Biolegend) and anti-
CD40 PE (Ancell), followed by staining with Streptavidin PE-Cy7 (BD).
Data were collected using an LSRII flow cytometer (BD). Data files were
analysed using FlowJo software (Tree Star, Inc.).
LPS levels
EDTA (ethylenediaminetetraacetic acid) plasma samples were diluted
1 to 10 with endotoxin-free water and incubated for 10min at 708C.
Plasma LPS was quantified with the LAL Endochrome Kit (Charles-
River) according to the manufacturer’s protocol for low range
detection. Additionally the same samples were analysed with the LAL
QCL-1000 Kit (Lonza) and two kinetic kits (Endosafe Endochrome-K,
CharlesRiver and LAL Kinetic QCL, Lonza). Only data from the LAL
Endochrome Kit are shown as it proved to be the most sensitive
assay.
Soluble CD14 (sCD14) and cytokines
Plasma samples were tested for IL-2, -6, -10, IFN-g and TNF-a by
Cytometric Bead Array (BD) according to the manufacturer’s protocol.
IFN-a (Interferonsource) and sCD14 (R&D Systems) were measured by
commercially available ELISA (enzyme-linked immunosorbent assay)
kits according to the manufacturer’s protocols.
In vitro proliferation assays
CD4þ T cells from healthy CMV-positive donors were purified from
freshly isolated PBMCs by magnetic microbeads (Miltenyi) and labelled
with 5mM CFSE (carboxyfluorescein diacetate, succinimidyl ester,
Invitrogen). For LPS activation, MDDCs were loaded over-night with
0.1 or 0.01mg/ml CMV pp65 and IE-1 peptide pools and then
stimulated for 24h with 0.5mg/ml LPS (Sigma). For iHIV activation,
MDDCs were stimulated for 24h with AT-2 iHIV particles (50mg/ml p24)
or matching concentrations of control microvesicles (gift from J. Lifson)
and then pulsed for 1h with CMV peptide pools. Purified CD4þ T cells
were stimulated with 1% autologous MDDCs for 6 days and analysed by
flow cytometry as described above. This assay was performed in RPMI-
medium (Invitrogen) supplemented with 10% human serum.
Statistical analysis
Spearman’s correlation analysis with a two-tailed test of significance
was performed using SPSS software (SPSS). Dynamical correlation
analysis was performed as described elsewhere (Dubin & Mueller, 2005).
This method quantifies the covariation of components of multivariate
longitudinal data. It estimates a correlation for the trend rather than the
magnitude of the measured parameters. Standard R-Software was used
for analysis. p-Values <0.01 were considered significant.
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The paper explained
PROBLEM:
Continuous depletion of CD4þ T helper cells, key players of the
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